Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study

Fig. 2

Serum levels of IL-17A, IL-17F, IL-22, CRP, SAA, and IL-6 in participants with TNFi-IR PsA from COSMOS compared with healthy controls over time. Participants randomized to placebo crossed over to guselkumab at Week 16 (early escape; dotted line; n = 24) or at Week 24 (per protocol; dashed line; n = 26). Statistics based on general linear model. Error bars represent 1 standard error. *Indicates statistical significance versus placebo by p < 0.05 and |fold difference | ≥ 1.4. #Indicates statistical significance versus baseline by p < 0.05 and |fold difference | ≥ 1.4. †Indicates statistical significance versus healthy controls by p < 0.05 and |fold difference | ≥ 1.4. CRP, C-reactive protein; GUS, guselkumab; IFN, interferon; IL, interleukin; PBO, placebo; PsA, psoriatic arthritis; Q8W, every 8 weeks; SAA, serum amyloid A; TNFi-IR, tumor necrosis factor inhibitor-inadequate response

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us